Genetics of Gastric Cancer

Matthew S. Strand, Albert Lockhart, Ryan C. Fields

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.

Original languageEnglish (US)
Pages (from-to)345-370
Number of pages26
JournalSurgical Clinics of North America
Volume97
Issue number2
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Stomach Neoplasms
Immunotherapy
Patient Selection
Melanoma
Therapeutics
Breast Neoplasms
Mortality
Incidence
Population
Neoplasms
ramucirumab
Trastuzumab

Keywords

  • Gastric adenocarcinoma
  • Gastric cancer
  • Genetics
  • Hereditary gastric cancer syndromes
  • Immunotherapy
  • Prophylactic gastrectomy
  • Targeted therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Genetics of Gastric Cancer. / Strand, Matthew S.; Lockhart, Albert; Fields, Ryan C.

In: Surgical Clinics of North America, Vol. 97, No. 2, 01.04.2017, p. 345-370.

Research output: Contribution to journalReview article

Strand, Matthew S. ; Lockhart, Albert ; Fields, Ryan C. / Genetics of Gastric Cancer. In: Surgical Clinics of North America. 2017 ; Vol. 97, No. 2. pp. 345-370.
@article{df07b45487544141b553c5f09bafe460,
title = "Genetics of Gastric Cancer",
abstract = "Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.",
keywords = "Gastric adenocarcinoma, Gastric cancer, Genetics, Hereditary gastric cancer syndromes, Immunotherapy, Prophylactic gastrectomy, Targeted therapy",
author = "Strand, {Matthew S.} and Albert Lockhart and Fields, {Ryan C.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1016/j.suc.2016.11.009",
language = "English (US)",
volume = "97",
pages = "345--370",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Genetics of Gastric Cancer

AU - Strand, Matthew S.

AU - Lockhart, Albert

AU - Fields, Ryan C.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.

AB - Gastric cancer represents a major cause of cancer mortality worldwide despite a declining incidence. New molecular classification schemes developed from genomic and molecular analyses of gastric cancer have provided a framework for understanding this heterogenous disease, and early findings suggest these classifications will be relevant for designing and implementing new targeted therapies. The success of targeted therapy and immunotherapy in breast cancer and melanoma, respectively, has not been duplicated in gastric cancer, but trastuzumab and ramucirumab have demonstrated efficacy in select populations. New markers that predict therapeutic response are needed to improve patient selection for both targeted and immunotherapies.

KW - Gastric adenocarcinoma

KW - Gastric cancer

KW - Genetics

KW - Hereditary gastric cancer syndromes

KW - Immunotherapy

KW - Prophylactic gastrectomy

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85015700441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015700441&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2016.11.009

DO - 10.1016/j.suc.2016.11.009

M3 - Review article

C2 - 28325191

AN - SCOPUS:85015700441

VL - 97

SP - 345

EP - 370

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 2

ER -